Arcutis Biotherapeutics’ $150 Million Shares Offering

Latham & Watkins advised Arcutis Biotherapeutics, Inc. in the offering, while Cooley represented the underwriters.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced the pricing of its underwritten public…

This content is for members only.
Login to Read More Join Now
Laura Testa

Author: Laura Testa

This content is for members only.
Login to Read More Join Now